Johnson & Johnson Stock News

Healthcare stocks certainly haven't set the world on fire lately. The S&P Health Care Index is up 3% so far in 2024 compared to an 8% gain in the benchmark S&P 500.

Johnson & Johnson (NYSE: JNJ ) stock is a hot topic on Wednesday after the company proposed a $6.5 billion settlement over talc cancer lawsuits. Johnson & Johnson is seeking to bankrupt LTL Management

Through a bankruptcy filing of its subsidiary company, J&J will be able to resolve about 99.75% of the pending talc lawsuits against the company and its affiliates in the U.S.

Johnson & Johnson (JNJ) shares rose in early trading Wednesday after the company announced a plan that would resolve nearly all pending litigation over claims that its talc powder caused ovarian cance

Johnson & Johnson (JNJ.N) announced on Wednesday a significant move towards resolving ongoing litigation over its baby powder and other talc products, with a proposed settlement amounting to $6.475 bi

Johnson & Johnson JNJ, -1.52% unveiled its latest plan to settle ovarian cancer talc claims with the news of a consensual “prepackaged” reorganization of its LTL Management LLC unit, which manages

Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian

Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.

The healthcare industry has experienced unprecedented growth in recent years due to the global pandemic. However, as COVID-19 began to ease, the immense growth of the healthcare industry is expected t

When the biggest names on Wall Street make an investment decision, the world listens. As the first quarter of 2024 comes to a close, SEC 13-F filings are coming in hot, showing investors where some of

The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.

A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S

Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations (I'm not sure if the metaverse qualifies rig

Johnson & Johnson has a higher credit rating than the U.S. Federal Government. The healthcare giant is in the elite class of Dividend Kings.

One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable co